abstract: OBJECTIVE: We studied high-resolution CT of @entity5 and @entity7 to determine whether differences-other than the frequency of associated pleural changes-could be discerned between the two diseases. MATERIALS AND METHODS: High-resolution CT scans of 80 @entity0 with @entity5 and 80 @entity0 with @entity7 were retrospectively reviewed. Two chest radiologists assessed the type and distribution of parenchymal and @entity4 on high-resolution CT. RESULTS: @entity2 (65/80), subpleural curvilinear lines (55/80), mosaic perfusion (39/80), and parenchymal bands (38/80) were more common in @entity0 with @entity5 (p < 0.0001). Visible intralobular bronchioles (62/80), bronchiolectasis within fibrotic consolidations (47/80), and honeycombing (61/80) were more common in @entity0 with @entity7 (p < 0.0001). The frequencies of interlobular septal thickening, ground-glass opacities, fibrotic consolidation, and @entity6 were similar in both groups. Parenchymal bands and fibrotic consolidation were more commonly seen (p < 0. 05) in @entity0 with @entity5 associated with @entity4 (n = 66) than in @entity0 with @entity5 without @entity4 (n = 14). Also, statistically significant differences were noted between high-resolution CT findings of @entity0 with @entity5 without @entity4 and those of @entity0 with @entity7 , except for parenchymal bands. CONCLUSION: Specific combinations of high-resolution CT findings strongly suggest either @entity5 or @entity7 . We found that CT findings that might have represented @entity1 in the subpleural region were more prominent in @entity0 with @entity5 than in those with @entity7 , whereas @entity3 was more prominent in @entity0 with @entity7 than in those with @entity5 .

title: High-resolution CT of @entity5 and XXXX .

answer: @entity7


abstract: BACKGROUND: Despite recommendations for annual vaccinations against @entity2 , many older African-Americans do not receive this vaccine. For 1 month in our private medical offices, we conducted a survey to estimate the vaccination rate for our practice, the reasons why older African-Americans declined to be vaccinated, and any impact we could make on their misconceptions about its safety and efficacy. SETTING: The study was conducted in a three-physician private practice of geriatric/internal medicine in the borough of Queens, New York. @entity0 : 231 consecutive community-residing @entity0 aged 65 or older were evaluated starting in October 1999. METHODS: A total of 231 @entity0 aged 65 to 96 were given a questionnaire asking if they planned to or had already received the @entity2 vaccine for the 1999-2000 season. Those who had no intention of taking the vaccine were asked why. Categories included: Vaccine not recommended/not recommended strongly enough, vaccine has no benefit, I became ill after being vaccinated, too afraid, I heard it makes @entity0 sick, no special reason, @entity1 to eggs, never had the flu. Those who refused had a brief discussion with their physician and it was noted whether they agreed later to be vaccinated. Ten @entity0 who were not black were excluded. RESULTS: Forty-four percent (98/221) of @entity0 intended to be vaccinated before discussion with their physician. After discussion with their physician about potential side effects, efficacy,safety, the percentage rose to 63% (139/221). This compares favorably with the national health objective of 60% or greater for the year 2000 in this population. CONCLUSIONS: The primary care physician had a significant impact on the increase of the @entity2 vaccination rate among older African-Americans in our study from 44 to 63%.

title: Elderly African-Americans and the XXXX vaccine: the impact of the primary care physician.

answer: @entity2


abstract: OBJECTIVE: To evaluate the clinical efficacy of one-stage surgical management for @entity4 . METHODS: Fifty-seven @entity0 with thoracic, thoracolumbar and lumbar @entity4 were treated surgically by a single stage procedure from Jan 1996 to Jan 2001, including anterior resection, interbody outografting and anterior instrumentation in 35 cases, posterior debridement and posterior instrumentation in 16 cases, and posterior instrumentation and anterior resection plus interbody autografting in 6 cases. @entity2 -alloy spinal implants were used in 38 cases and stainless steel implants in other 19 cases. Except for three @entity0 , other 54 @entity0 were followed up for one to five years (mean 2.2 years). RESULTS: All these @entity0 had their incision healed by first intention without @entity1 or sinus formation, and no recurrence of @entity4 was noted in any @entity0 during the follow-up period. @entity3 correction were achieved by 21.6 degrees on the average postoperatively. There was a mild loss (2 degrees - 4 degrees) of @entity3 correction during follow-up period. Spinal solid fusion at the interface between the graft and adjacent vertebral bodies was shown radiologically in 3.8 months on the average. CONCLUSION: One-stage surgical management has more advantages in that it can completes all the aspects of surgical treatment for @entity4 . Anterior or posterior instrumentation with @entity2 -alloy or stainless steel spinal implants is safe, The selection of one-stage surgical procedure should be planed individually.

title: [One-stage surgical management for XXXX ].

answer: @entity4


abstract: UNASSIGNED: @entity10 is a highly potent b2 -adrenoceptor-selective agonist, which is a muscle growth promoter in many animal species. @entity11 / @entity5 inhibition reverses skeletal muscle loss and prolongs survival of tumor-bearing animals. The aim of the present investigation was to evaluate the effects of a combination of the soluble @entity11 receptor ActRIIB (sActRIIB) and the b2 -agonist @entity10 in the cachectic @entity1 model (LLC). The combination of @entity10 and sActRIIB was extremely effective in reversing @entity7 associated with experimental @entity3 @entity8 in @entity4 . Muscle weights from @entity3 -bearing animals were completely recovered following treatment and this was also reflected in the measured grip strength. This combination increased food intake both in control and @entity3 -bearing animals. The double treatment also prolonged survival significantly without affecting the weight and growth of the primary @entity3 . In addition, it significantly reduced the number of @entity2 . Concerning the mechanisms for the preservation of muscle mass during @entity8 , the effects of @entity10 and sActRIIB seemed to be additive, since @entity10 reduced the rate of protein degradation (as measured in vitro as @entity9 release, using incubated isolated individual muscles) while sActRIIB only affected protein synthesis (as measured in vivo using tritiated @entity6 ). @entity10 also increased the rate of protein synthesis and this seemed to be favoured by the presence of sActRIIB. Combining @entity10 and sActRIIB seemed to be a very promising treatment for experimental @entity3 @entity8 . Further studies in @entity0 @entity0 are necessary and may lead to a highly effective treatment option for @entity7 associated with @entity3 . This article is protected by copyright. All rights reserved.

title: Complete reversal of XXXX in experimental @entity3 @entity8 : Additive effects of @entity5 type II receptor inhibition and beta-2 agonist.

answer: @entity7


abstract: UNASSIGNED: @entity10 is a highly potent b2 -adrenoceptor-selective agonist, which is a muscle growth promoter in many animal species. @entity11 / @entity5 inhibition reverses skeletal muscle loss and prolongs survival of tumor-bearing animals. The aim of the present investigation was to evaluate the effects of a combination of the soluble @entity11 receptor ActRIIB (sActRIIB) and the b2 -agonist @entity10 in the cachectic @entity1 model (LLC). The combination of @entity10 and sActRIIB was extremely effective in reversing @entity7 associated with experimental @entity3 @entity8 in @entity4 . Muscle weights from @entity3 -bearing animals were completely recovered following treatment and this was also reflected in the measured grip strength. This combination increased food intake both in control and @entity3 -bearing animals. The double treatment also prolonged survival significantly without affecting the weight and growth of the primary @entity3 . In addition, it significantly reduced the number of @entity2 . Concerning the mechanisms for the preservation of muscle mass during @entity8 , the effects of @entity10 and sActRIIB seemed to be additive, since @entity10 reduced the rate of protein degradation (as measured in vitro as @entity9 release, using incubated isolated individual muscles) while sActRIIB only affected protein synthesis (as measured in vivo using tritiated @entity6 ). @entity10 also increased the rate of protein synthesis and this seemed to be favoured by the presence of sActRIIB. Combining @entity10 and sActRIIB seemed to be a very promising treatment for experimental @entity3 @entity8 . Further studies in @entity0 @entity0 are necessary and may lead to a highly effective treatment option for @entity7 associated with @entity3 . This article is protected by copyright. All rights reserved.

title: Complete reversal of @entity7 in experimental @entity3 XXXX : Additive effects of @entity5 type II receptor inhibition and beta-2 agonist.

answer: @entity8


abstract: UNASSIGNED: @entity10 is a highly potent b2 -adrenoceptor-selective agonist, which is a muscle growth promoter in many animal species. @entity11 / @entity5 inhibition reverses skeletal muscle loss and prolongs survival of tumor-bearing animals. The aim of the present investigation was to evaluate the effects of a combination of the soluble @entity11 receptor ActRIIB (sActRIIB) and the b2 -agonist @entity10 in the cachectic @entity1 model (LLC). The combination of @entity10 and sActRIIB was extremely effective in reversing @entity7 associated with experimental @entity3 @entity8 in @entity4 . Muscle weights from @entity3 -bearing animals were completely recovered following treatment and this was also reflected in the measured grip strength. This combination increased food intake both in control and @entity3 -bearing animals. The double treatment also prolonged survival significantly without affecting the weight and growth of the primary @entity3 . In addition, it significantly reduced the number of @entity2 . Concerning the mechanisms for the preservation of muscle mass during @entity8 , the effects of @entity10 and sActRIIB seemed to be additive, since @entity10 reduced the rate of protein degradation (as measured in vitro as @entity9 release, using incubated isolated individual muscles) while sActRIIB only affected protein synthesis (as measured in vivo using tritiated @entity6 ). @entity10 also increased the rate of protein synthesis and this seemed to be favoured by the presence of sActRIIB. Combining @entity10 and sActRIIB seemed to be a very promising treatment for experimental @entity3 @entity8 . Further studies in @entity0 @entity0 are necessary and may lead to a highly effective treatment option for @entity7 associated with @entity3 . This article is protected by copyright. All rights reserved.

title: Complete reversal of @entity7 in experimental XXXX @entity8 : Additive effects of @entity5 type II receptor inhibition and beta-2 agonist.

answer: @entity3


abstract: UNASSIGNED: @entity10 is a highly potent b2 -adrenoceptor-selective agonist, which is a muscle growth promoter in many animal species. @entity11 / @entity5 inhibition reverses skeletal muscle loss and prolongs survival of tumor-bearing animals. The aim of the present investigation was to evaluate the effects of a combination of the soluble @entity11 receptor ActRIIB (sActRIIB) and the b2 -agonist @entity10 in the cachectic @entity1 model (LLC). The combination of @entity10 and sActRIIB was extremely effective in reversing @entity7 associated with experimental @entity3 @entity8 in @entity4 . Muscle weights from @entity3 -bearing animals were completely recovered following treatment and this was also reflected in the measured grip strength. This combination increased food intake both in control and @entity3 -bearing animals. The double treatment also prolonged survival significantly without affecting the weight and growth of the primary @entity3 . In addition, it significantly reduced the number of @entity2 . Concerning the mechanisms for the preservation of muscle mass during @entity8 , the effects of @entity10 and sActRIIB seemed to be additive, since @entity10 reduced the rate of protein degradation (as measured in vitro as @entity9 release, using incubated isolated individual muscles) while sActRIIB only affected protein synthesis (as measured in vivo using tritiated @entity6 ). @entity10 also increased the rate of protein synthesis and this seemed to be favoured by the presence of sActRIIB. Combining @entity10 and sActRIIB seemed to be a very promising treatment for experimental @entity3 @entity8 . Further studies in @entity0 @entity0 are necessary and may lead to a highly effective treatment option for @entity7 associated with @entity3 . This article is protected by copyright. All rights reserved.

title: Complete reversal of @entity7 in experimental @entity3 @entity8 : Additive effects of XXXX type II receptor inhibition and beta-2 agonist.

answer: @entity5


abstract: AIMS: To establish a clinical, histopathological, and genetic diagnosis in two unrelated @entity6 ( @entity6 ). METHODS: Genomic DNA was extracted from peripheral blood leucocytes of all members participating in the study. Exons 4 and 12 of the @entity0 @entity7 ( @entity7 ) gene were amplified by polymerase chain reaction. The mutation and polymorphism were identified by direct sequencing and restriction digest analysis. A review of the @entity0 ' clinical symptoms and signs was undertaken and a histopathological study on corneal specimen obtained from the proband of one family after keratoplasty was performed. RESULTS: A heterozygous G to A transition at the second @entity2 position of codon 124 of @entity7 gene was detected in all affected members of both families. This mutation changes an @entity1 residue to a @entity4 . The clinical diagnosis for @entity6 was more evident with advancing age. Histopathological study revealed granular deposits in the anterior stroma and occasional positive Congo red areas of @entity3 in the mid to deep stroma typical of @entity6 . CONCLUSIONS: This is the first report of @entity6 families in the United Kingdom and, furthermore, of @entity7 gene mutation in British @entity0 with this rare type of @entity5 . The results indicate that @entity7 gene screening along with clinical and histopathological examinations is essential for the diagnosis and clinical management of @entity5 .

title: A clinical, histopathological, and genetic study of XXXX in British families.

answer: @entity6


abstract: AIMS: To investigate the manifestations and severity of @entity6 in @entity0 and to identify the risk and specific causes of @entity7 in this population. METHODS: Retrospective study of data of 123 consecutive @entity0 examined with active @entity6 and the onset of @entity8 before the age of 16 years. Numerous variables were assessed including age and sex distribution, laboratory data, the presence of @entity4 , onset and course of @entity2 , clinical features and complications, therapeutic strategies and their outcomes, final visual acuity, and characteristics associated with poor visual outcome. RESULTS: @entity4 was observed in 36/123 @entity0 (29%), with @entity10 being the most frequent (25/123, 20%). @entity9 was diagnosed in 12/23 @entity0 with posterior @entity6 (52%; 10% of all with @entity6 ). @entity2 required systemic drugs in 57 (46%) @entity0 . Ocular complications were observed in 93 @entity0 (76%), of which the most common was @entity3 (43/123, 35%). Intraocular surgery was required in 35 @entity0 (28%; in total 75 procedures). Three @entity0 (2%) became @entity7 and an additional 20/121 (17%) had one @entity7 caused by @entity6 . The most frequent causes of @entity7 were @entity11 in the macular area and @entity5 in contrast with @entity1 ( @entity1 ) in adults. CONCLUSIONS: @entity6 in childhood is a potentially blinding disease, in the majority of @entity0 characterised by a chronic course and a high complication rate.

title: Visual loss in XXXX of childhood.

answer: @entity6


abstract: Investigation of MR @entity0 with 3p aberrations led to the identification of the translocation breakpoint in intron five of the neural Cell Adhesion L1-Like (CALL or @entity5 ) gene in a @entity0 with non-specific @entity4 and 46,Y, t(X;3)(p22.1;p26.3). The Xp breakpoint does not seem to affect a known or predicted gene. Moreover, a fusion transcript with the CALL gene could not be detected and no mutations were identified on the second allele. CALL is highly expressed in the central and peripheral nervous system, like the @entity1 ortholog 'close homolog to L1' ( @entity6 ). @entity6 expression levels in the hippocampus of @entity6 (+/-) @entity1 were half of those obtained in wild-type littermates, reflecting a gene dosage effect. Timm staining and synaptophysin immunohistochemistry of the hippocampus showed focal groups of ectopic mossy fiber synapses in the lateral CA3 region, outside the trajectory of the infra-pyramidal mossy fiber bundle in @entity6 (-/-) and @entity6 (+/-) @entity1 . Behavioral assessment demonstrated mild alterations in the @entity6 (-/-) animals. In the probe trial of the Morris Water Maze test, @entity6 (-/-) @entity1 displayed an altered exploratory pattern. In addition, these @entity1 were significantly more sociable and less @entity3 as demonstrated in social exploration tests. The @entity6 (+/-) @entity1 showed a phenotypic spectrum ranging from wild-type to knockout behavior. We hypothesize that a 50% reduction of CALL expression in the developing brain results in @entity2 . This suggests that the CALL gene at 3p26.3 is a prime candidate for an autosomal form of @entity4 . So far, mutation analysis of the CALL gene in @entity0 with non-specific MR did not reveal any disease-associated mutations.

title: CALL interrupted in a @entity0 with non-specific XXXX : gene dosage-dependent alteration of @entity1 brain development and behavior.

answer: @entity4


abstract: Investigation of MR @entity0 with 3p aberrations led to the identification of the translocation breakpoint in intron five of the neural Cell Adhesion L1-Like (CALL or @entity5 ) gene in a @entity0 with non-specific @entity4 and 46,Y, t(X;3)(p22.1;p26.3). The Xp breakpoint does not seem to affect a known or predicted gene. Moreover, a fusion transcript with the CALL gene could not be detected and no mutations were identified on the second allele. CALL is highly expressed in the central and peripheral nervous system, like the @entity1 ortholog 'close homolog to L1' ( @entity6 ). @entity6 expression levels in the hippocampus of @entity6 (+/-) @entity1 were half of those obtained in wild-type littermates, reflecting a gene dosage effect. Timm staining and synaptophysin immunohistochemistry of the hippocampus showed focal groups of ectopic mossy fiber synapses in the lateral CA3 region, outside the trajectory of the infra-pyramidal mossy fiber bundle in @entity6 (-/-) and @entity6 (+/-) @entity1 . Behavioral assessment demonstrated mild alterations in the @entity6 (-/-) animals. In the probe trial of the Morris Water Maze test, @entity6 (-/-) @entity1 displayed an altered exploratory pattern. In addition, these @entity1 were significantly more sociable and less @entity3 as demonstrated in social exploration tests. The @entity6 (+/-) @entity1 showed a phenotypic spectrum ranging from wild-type to knockout behavior. We hypothesize that a 50% reduction of CALL expression in the developing brain results in @entity2 . This suggests that the CALL gene at 3p26.3 is a prime candidate for an autosomal form of @entity4 . So far, mutation analysis of the CALL gene in @entity0 with non-specific MR did not reveal any disease-associated mutations.

title: CALL interrupted in a XXXX with non-specific @entity4 : gene dosage-dependent alteration of @entity1 brain development and behavior.

answer: @entity0


abstract: Investigation of MR @entity0 with 3p aberrations led to the identification of the translocation breakpoint in intron five of the neural Cell Adhesion L1-Like (CALL or @entity5 ) gene in a @entity0 with non-specific @entity4 and 46,Y, t(X;3)(p22.1;p26.3). The Xp breakpoint does not seem to affect a known or predicted gene. Moreover, a fusion transcript with the CALL gene could not be detected and no mutations were identified on the second allele. CALL is highly expressed in the central and peripheral nervous system, like the @entity1 ortholog 'close homolog to L1' ( @entity6 ). @entity6 expression levels in the hippocampus of @entity6 (+/-) @entity1 were half of those obtained in wild-type littermates, reflecting a gene dosage effect. Timm staining and synaptophysin immunohistochemistry of the hippocampus showed focal groups of ectopic mossy fiber synapses in the lateral CA3 region, outside the trajectory of the infra-pyramidal mossy fiber bundle in @entity6 (-/-) and @entity6 (+/-) @entity1 . Behavioral assessment demonstrated mild alterations in the @entity6 (-/-) animals. In the probe trial of the Morris Water Maze test, @entity6 (-/-) @entity1 displayed an altered exploratory pattern. In addition, these @entity1 were significantly more sociable and less @entity3 as demonstrated in social exploration tests. The @entity6 (+/-) @entity1 showed a phenotypic spectrum ranging from wild-type to knockout behavior. We hypothesize that a 50% reduction of CALL expression in the developing brain results in @entity2 . This suggests that the CALL gene at 3p26.3 is a prime candidate for an autosomal form of @entity4 . So far, mutation analysis of the CALL gene in @entity0 with non-specific MR did not reveal any disease-associated mutations.

title: CALL interrupted in a @entity0 with non-specific @entity4 : gene dosage-dependent alteration of XXXX brain development and behavior.

answer: @entity1


abstract: Somatic noxious stimulation can evoke profound cardiovascular responses by altering activity in the autonomic nervous system. This noxious stimulation attenuates the cardiac vagal baroreflex, a key cardiovascular homeostatic reflex. This attenuation is mediated via NK1 receptors expressed on GABAergic interneurones within the nucleus of the solitary tract (NTS). We have investigated the effect of noxious stimulation and exogenous substance @entity4 ) on the sympathetic component of the baroreflex. We recorded from the sympathetic chain in a decerebrate, artificially perfused @entity0 preparation. Noxious hindlimb pinch was without effect on the sympathetic baroreflex although the cardiac @entity2 was decreased (56 %, P < 0.01). Bilateral NTS microinjection of SP (500 fmol) produced a similar selective attenuation of the cardiac @entity2 (62 %, P < 0.005) without effect on the sympathetic baroreflex. Recordings from the cardiac sympathetic and vagal nerves confirmed the selectivity of the SP inhibition. Control experiments using a GABAA receptor agonist, @entity5 , indicated that both components of the baroreflex (parasympathetic and sympathetic) could be blocked from the NTS injection site. The NTS microinjection of a NK1 antagonist ( @entity6 ) in vivo attenuated the @entity3 . Our data suggest that noxious pinch releases SP within the NTS to selectively attenuate the cardiac vagal, but not the sympathetic, component of the baroreflex. This selective withdrawal of the cardiac vagal baroreflex seems to underlie the pinch-evoked @entity1 seen in vivo. Further, these findings confirm that baroreflex sympathetic and parasympathetic pathways diverge, and can be independently controlled, within the NTS.

title: Nociception attenuates parasympathetic but not sympathetic baroreflex via NK1 receptors in the XXXX nucleus tractus solitarii.

answer: @entity0


abstract: To maintain genome stability, DNA replication is strictly regulated to occur only once per cell cycle. In eukaryotes, the presence of 'licensing proteins' at replication origins during the G1 cell-cycle phase allows the formation of the pre-replicative complex. The removal of licensing proteins from chromatin during the S phase ensures that origins fire only once per cell cycle. Here we show that the @entity1 ubiquitin ligase temporally restricts DNA-replication licensing in @entity0 . Inactivation of @entity1 causes massive DNA re-replication, producing cells with up to 100C DNA content. The @entity0 orthologue of the replication-licensing factor @entity2 (refs 2, 3) is required for DNA replication. @entity0 @entity2 is present in G1-phase nuclei but disappears as cells enter S phase. In cells lacking @entity1 , @entity2 levels fail to decrease during S phase and instead remain constant in the re-replicating cells. Removal of one genomic copy of @entity2 suppresses the @entity1 re-replication phenotype. We propose that @entity1 prevents aberrant re-initiation of DNA replication, at least in part, by facilitating the degradation of @entity2 .

title: XXXX ubiquitin ligase maintains genome stability by restraining DNA-replication licensing.

answer: @entity1


abstract: The diagnosis of diffuse @entity3 means a very bad prognosis. The average survival of our own cases, controlled by autopsy, was 16.4 months (n = 36) for symptomatically treated @entity0 and 16.1 months (n = 26) for those treated with @entity2 and other cytotoxic drugs. The difference between the two groups is statistically without significance. @entity1 was applied in a third group. The drug was applied intrapleurally for cases with pleural fluid in doses of 20 to 30 mg, weekly during the first month of treatment and later on monthly. The effect will be controlled directly and during the continued treatment, using cytological examination of the sediment of the pleural fluid and by simultaneous measurement of the level of hyaluronic acid in the same fluid. The advantages of this method are the small dosage, the possibility of applying over a long time and few side effects. 21 @entity0 were treated: 9 without response, 8 lived for a longer period, 4 @entity0 are still alive. The average survival of all the 21 @entity0 observed is now 25.3 (8-79) months. The difference to an untreated control group of 36 @entity0 is proved as statistical significant in favour of the therapeutic group. @entity1 , linked with a really early diagnosis, seems to be a suitable drug for essentially improving the prognosis of disease.

title: Diffuse malignant mesothelioma of the pleura--intrapleural treatment with XXXX .

answer: @entity1


abstract: @entity4 in @entity2 ( @entity2 ) is common and occurs in 70% of @entity0 . The aim of the study was to evaluate autonomic mechanisms regulating cardiovascular system during tilt up test in @entity2 @entity0 . The examination was performed in 35 @entity0 with @entity2 (26 male and 9 female, mean age 60 +/- 9) and matched with gender and age 35 controls subjects (healthy volunteers, mean age 59 +/- 9). @entity0 were divided into two groups: group I--early stage of disease (n = 20) and group II--advanced stage of the disease (n = 15). The tilt test in @entity2 @entity0 and in the control group lasted 3 minutes. In both groups tilt test was performed with a head-up tilt position of 60 degrees (tilt table Manumed, Netherlands). In both groups 30:15 ratio were lower than in the control group 1.03 +/- 0.08, 0.97 +/- 0.09 v 1.23 +/- 0.1 respectively (p = 0.001). In the second group the heart-rate variability after the tilt test was lower 6.2 +/- 4/min than in the control group 10.2 +/- +/- 1.9/min and group I 8.8 +/- 4/min (p = 0.01). The decrease of the systolic pressure in response to the tilt test was the highest in group II (16 +/- 14 mmHg), in the control group 4 +/- 7 mmHg, in group I 13 +/- 11 mmHg (p = 0.001). @entity3 in @entity2 occurs in 36% of @entity0 in an early stage and in 47% of @entity0 in an advanced stage of the disease. The use of the tilt test enables the early diagnosis of @entity1 in @entity2 .

title: [Early diagnosis of XXXX in @entity2 ].

answer: @entity3


abstract: @entity4 in @entity2 ( @entity2 ) is common and occurs in 70% of @entity0 . The aim of the study was to evaluate autonomic mechanisms regulating cardiovascular system during tilt up test in @entity2 @entity0 . The examination was performed in 35 @entity0 with @entity2 (26 male and 9 female, mean age 60 +/- 9) and matched with gender and age 35 controls subjects (healthy volunteers, mean age 59 +/- 9). @entity0 were divided into two groups: group I--early stage of disease (n = 20) and group II--advanced stage of the disease (n = 15). The tilt test in @entity2 @entity0 and in the control group lasted 3 minutes. In both groups tilt test was performed with a head-up tilt position of 60 degrees (tilt table Manumed, Netherlands). In both groups 30:15 ratio were lower than in the control group 1.03 +/- 0.08, 0.97 +/- 0.09 v 1.23 +/- 0.1 respectively (p = 0.001). In the second group the heart-rate variability after the tilt test was lower 6.2 +/- 4/min than in the control group 10.2 +/- +/- 1.9/min and group I 8.8 +/- 4/min (p = 0.01). The decrease of the systolic pressure in response to the tilt test was the highest in group II (16 +/- 14 mmHg), in the control group 4 +/- 7 mmHg, in group I 13 +/- 11 mmHg (p = 0.001). @entity3 in @entity2 occurs in 36% of @entity0 in an early stage and in 47% of @entity0 in an advanced stage of the disease. The use of the tilt test enables the early diagnosis of @entity1 in @entity2 .

title: [Early diagnosis of @entity3 in XXXX ].

answer: @entity2


abstract: PURPOSE: Activating @entity7 genomic alterations are frequent in @entity3 ( @entity3 ), and there is an association between @entity5 ( @entity5 ) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting @entity5 with @entity8 , a @entity5 inhibitor with potent activity against @entity7 , in combination with radiation in @entity3 . EXPERIMENTAL DESIGN: The efficacy of @entity8 was assessed in vitro in 26 @entity3 cell lines with crystal violet proliferation assays, and changes in @entity5 signaling were measured by Western blot analysis. @entity2 and radiosensitization were assessed with @entity6 staining via flow cytometry and clonogenic survival assays, respectively. DNA damage repair was assessed with immunofluorescence for yH2AX foci, and cell cycle analysis was performed with flow cytometry. In vivo efficacy of @entity8 and radiation was assessed in xenografts implanted into @entity1 . RESULTS: @entity8 inhibited potently @entity5 signaling and displayed greater antiproliferative activity in @entity3 cell lines with @entity7 mutations or amplification, whereas cell lines with @entity4 alterations were relatively resistant to its effects. Pretreatment with @entity8 radiosensitized @entity7 -mutant @entity3 cells, enhanced radiation-induced apoptosis, @entity0 repair, and prolonged G2-M arrest following irradiation. Furthermore, combined @entity8 and radiation was more effective than either treatment alone in vivo in subcutaneous xenograft models. CONCLUSIONS: @entity8 has increased potency in @entity3 cell lines harboring @entity7 -activating aberrations. Further, combined @entity8 and radiotherapy was more efficacious than either treatment alone in @entity7 -altered @entity3 in vitro and in vivo. This strategy warrants further clinical investigation. Clin Cancer Res; 1-11.   2015 AACR.

title: Taselisib ( @entity8 ), a Potent b-Sparing Small Molecule Inhibitor of @entity5 , Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating XXXX Alterations.

answer: @entity7


abstract: PURPOSE: Activating @entity7 genomic alterations are frequent in @entity3 ( @entity3 ), and there is an association between @entity5 ( @entity5 ) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting @entity5 with @entity8 , a @entity5 inhibitor with potent activity against @entity7 , in combination with radiation in @entity3 . EXPERIMENTAL DESIGN: The efficacy of @entity8 was assessed in vitro in 26 @entity3 cell lines with crystal violet proliferation assays, and changes in @entity5 signaling were measured by Western blot analysis. @entity2 and radiosensitization were assessed with @entity6 staining via flow cytometry and clonogenic survival assays, respectively. DNA damage repair was assessed with immunofluorescence for yH2AX foci, and cell cycle analysis was performed with flow cytometry. In vivo efficacy of @entity8 and radiation was assessed in xenografts implanted into @entity1 . RESULTS: @entity8 inhibited potently @entity5 signaling and displayed greater antiproliferative activity in @entity3 cell lines with @entity7 mutations or amplification, whereas cell lines with @entity4 alterations were relatively resistant to its effects. Pretreatment with @entity8 radiosensitized @entity7 -mutant @entity3 cells, enhanced radiation-induced apoptosis, @entity0 repair, and prolonged G2-M arrest following irradiation. Furthermore, combined @entity8 and radiation was more effective than either treatment alone in vivo in subcutaneous xenograft models. CONCLUSIONS: @entity8 has increased potency in @entity3 cell lines harboring @entity7 -activating aberrations. Further, combined @entity8 and radiotherapy was more efficacious than either treatment alone in @entity7 -altered @entity3 in vitro and in vivo. This strategy warrants further clinical investigation. Clin Cancer Res; 1-11.   2015 AACR.

title: Taselisib ( XXXX ), a Potent b-Sparing Small Molecule Inhibitor of @entity5 , Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating @entity7 Alterations.

answer: @entity8


abstract: PURPOSE: Activating @entity7 genomic alterations are frequent in @entity3 ( @entity3 ), and there is an association between @entity5 ( @entity5 ) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting @entity5 with @entity8 , a @entity5 inhibitor with potent activity against @entity7 , in combination with radiation in @entity3 . EXPERIMENTAL DESIGN: The efficacy of @entity8 was assessed in vitro in 26 @entity3 cell lines with crystal violet proliferation assays, and changes in @entity5 signaling were measured by Western blot analysis. @entity2 and radiosensitization were assessed with @entity6 staining via flow cytometry and clonogenic survival assays, respectively. DNA damage repair was assessed with immunofluorescence for yH2AX foci, and cell cycle analysis was performed with flow cytometry. In vivo efficacy of @entity8 and radiation was assessed in xenografts implanted into @entity1 . RESULTS: @entity8 inhibited potently @entity5 signaling and displayed greater antiproliferative activity in @entity3 cell lines with @entity7 mutations or amplification, whereas cell lines with @entity4 alterations were relatively resistant to its effects. Pretreatment with @entity8 radiosensitized @entity7 -mutant @entity3 cells, enhanced radiation-induced apoptosis, @entity0 repair, and prolonged G2-M arrest following irradiation. Furthermore, combined @entity8 and radiation was more effective than either treatment alone in vivo in subcutaneous xenograft models. CONCLUSIONS: @entity8 has increased potency in @entity3 cell lines harboring @entity7 -activating aberrations. Further, combined @entity8 and radiotherapy was more efficacious than either treatment alone in @entity7 -altered @entity3 in vitro and in vivo. This strategy warrants further clinical investigation. Clin Cancer Res; 1-11.   2015 AACR.

title: Taselisib ( @entity8 ), a Potent b-Sparing Small Molecule Inhibitor of XXXX , Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating @entity7 Alterations.

answer: @entity5


abstract: UNASSIGNED: Previous studies have shown that @entity8 pesticide (OP) exposure is associated with oxidative stress. @entity10 ( @entity7 ) is an OP widely used in agriculture, which is regarded as a highly toxic pesticide and it is a potent inhibitor of acetylcholinesterase. The aim of this study was to evaluate whether @entity7 can induce oxidative stress at low concentrations in primary cultures of @entity0 peripheral blood mononuclear cells (PBMCs). PBMCs from healthy individuals were exposed to @entity7 (0-80 mg/L) for 0-72 h. We performed the @entity2 and neutral-red assays to assess the @entity3 . As indicators of oxidative stress, the levels of reactive @entity1 species (ROS) were assessed using flow cytometry, and the @entity4 ( @entity5 ) and @entity6 ( @entity9 ) levels were determined. @entity7 decreased the viability of PBMCs in a dose-dependent manner. At concentrations of 3, 10, or 20 mg/L for 24 h, @entity7 increased the ROS production significantly compared with the vehicle control. Similarly, @entity7 increased the levels of @entity5 at the same concentrations that increased ROS (10 and 20 mg/L); however, no changes in @entity9 levels were observed. These results suggest that @entity7 increased the generation of oxidative stress in PBMCs.    2015 Wiley Periodicals, Inc. Environ Toxicol, 2015.

title: XXXX induces @entity3 and oxidative stress in @entity0 peripheral blood mononuclear cells.

answer: @entity10


abstract: UNASSIGNED: Previous studies have shown that @entity8 pesticide (OP) exposure is associated with oxidative stress. @entity10 ( @entity7 ) is an OP widely used in agriculture, which is regarded as a highly toxic pesticide and it is a potent inhibitor of acetylcholinesterase. The aim of this study was to evaluate whether @entity7 can induce oxidative stress at low concentrations in primary cultures of @entity0 peripheral blood mononuclear cells (PBMCs). PBMCs from healthy individuals were exposed to @entity7 (0-80 mg/L) for 0-72 h. We performed the @entity2 and neutral-red assays to assess the @entity3 . As indicators of oxidative stress, the levels of reactive @entity1 species (ROS) were assessed using flow cytometry, and the @entity4 ( @entity5 ) and @entity6 ( @entity9 ) levels were determined. @entity7 decreased the viability of PBMCs in a dose-dependent manner. At concentrations of 3, 10, or 20 mg/L for 24 h, @entity7 increased the ROS production significantly compared with the vehicle control. Similarly, @entity7 increased the levels of @entity5 at the same concentrations that increased ROS (10 and 20 mg/L); however, no changes in @entity9 levels were observed. These results suggest that @entity7 increased the generation of oxidative stress in PBMCs.    2015 Wiley Periodicals, Inc. Environ Toxicol, 2015.

title: @entity10 induces XXXX and oxidative stress in @entity0 peripheral blood mononuclear cells.

answer: @entity3


abstract: UNASSIGNED: Previous studies have shown that @entity8 pesticide (OP) exposure is associated with oxidative stress. @entity10 ( @entity7 ) is an OP widely used in agriculture, which is regarded as a highly toxic pesticide and it is a potent inhibitor of acetylcholinesterase. The aim of this study was to evaluate whether @entity7 can induce oxidative stress at low concentrations in primary cultures of @entity0 peripheral blood mononuclear cells (PBMCs). PBMCs from healthy individuals were exposed to @entity7 (0-80 mg/L) for 0-72 h. We performed the @entity2 and neutral-red assays to assess the @entity3 . As indicators of oxidative stress, the levels of reactive @entity1 species (ROS) were assessed using flow cytometry, and the @entity4 ( @entity5 ) and @entity6 ( @entity9 ) levels were determined. @entity7 decreased the viability of PBMCs in a dose-dependent manner. At concentrations of 3, 10, or 20 mg/L for 24 h, @entity7 increased the ROS production significantly compared with the vehicle control. Similarly, @entity7 increased the levels of @entity5 at the same concentrations that increased ROS (10 and 20 mg/L); however, no changes in @entity9 levels were observed. These results suggest that @entity7 increased the generation of oxidative stress in PBMCs.    2015 Wiley Periodicals, Inc. Environ Toxicol, 2015.

title: @entity10 induces @entity3 and oxidative stress in XXXX peripheral blood mononuclear cells.

answer: @entity0


abstract: BACKGROUND: Mouthrinses are widely utilized in daily oral and dental hygiene to control plaque. However, most commercially available mouthrinses contain @entity1 as an excipient. Most studies have focused on the clinical side effects related to the alcoholic fraction of mouthrinses, overlooking @entity1 metabolism in the mouth. Due to this oral enzymatic process, the well-recognized toxic compound @entity2 is emitted in the mouth. Since gingival fibroblasts play a key role in oral connective tissue health maintenance, we investigated the effects of different doses of @entity2 on @entity0 gingival fibroblasts (HGFs) in order to better define the effects of @entity1 -containing mouthrinses on oral tissue. METHODS: Cultured HGFs were exposed to different concentrations of @entity2 (10(-4) M to 10(-2) M). The cell adhesion rate was measured after a 3-hour incubation period, and cell viability over a 5-day period. In order to assess the reversibility of the damage produced by @entity2 , treatment was interrupted at critical doses (10(-3) M and 3 x 10(-3) M), and cell viability was evaluated on the third and fifth day of incubation. The @entity3 cytoskeleton was studied by immunocytochemical technique, and internal cell structures were observed with transmission electron microscopy to evaluate the morphological changes due to @entity2 . RESULTS: The results showed that @entity2 produced a dose- and time-dependent inhibition on cell adhesion and viability, together with disruption of cytoskeletal structures and cytoplasmic organelles. Nevertheless, these quantitative and qualitative damages were reversible when the treatment was interrupted. CONCLUSIONS: Although more knowledge is necessary, our results suggest that these deleterious effects may also occur in vivo. Pending further investigations, clinicians should be alerted to the potentially adverse effect of @entity1 -containing mouthrinses and, to promote oral health, @entity0 should be warned about improper use of these products.

title: Mouthrinses with XXXX : cytotoxic effects on @entity0 gingival fibroblasts in vitro.

answer: @entity1


abstract: BACKGROUND: Mouthrinses are widely utilized in daily oral and dental hygiene to control plaque. However, most commercially available mouthrinses contain @entity1 as an excipient. Most studies have focused on the clinical side effects related to the alcoholic fraction of mouthrinses, overlooking @entity1 metabolism in the mouth. Due to this oral enzymatic process, the well-recognized toxic compound @entity2 is emitted in the mouth. Since gingival fibroblasts play a key role in oral connective tissue health maintenance, we investigated the effects of different doses of @entity2 on @entity0 gingival fibroblasts (HGFs) in order to better define the effects of @entity1 -containing mouthrinses on oral tissue. METHODS: Cultured HGFs were exposed to different concentrations of @entity2 (10(-4) M to 10(-2) M). The cell adhesion rate was measured after a 3-hour incubation period, and cell viability over a 5-day period. In order to assess the reversibility of the damage produced by @entity2 , treatment was interrupted at critical doses (10(-3) M and 3 x 10(-3) M), and cell viability was evaluated on the third and fifth day of incubation. The @entity3 cytoskeleton was studied by immunocytochemical technique, and internal cell structures were observed with transmission electron microscopy to evaluate the morphological changes due to @entity2 . RESULTS: The results showed that @entity2 produced a dose- and time-dependent inhibition on cell adhesion and viability, together with disruption of cytoskeletal structures and cytoplasmic organelles. Nevertheless, these quantitative and qualitative damages were reversible when the treatment was interrupted. CONCLUSIONS: Although more knowledge is necessary, our results suggest that these deleterious effects may also occur in vivo. Pending further investigations, clinicians should be alerted to the potentially adverse effect of @entity1 -containing mouthrinses and, to promote oral health, @entity0 should be warned about improper use of these products.

title: Mouthrinses with @entity1 : cytotoxic effects on XXXX gingival fibroblasts in vitro.

answer: @entity0


abstract: BACKGROUND: Levator ani muscle complex plays an important role in pelvic support and defects or laxity in this muscle complex contributes to pelvic organ prolapse and recurrence after surgical repair. OBJECTIVE: The purpose of this study was to determine whether estimated levator ani subtended volume can predict surgical outcomes for laparoscopic bilateral uterosacral ligament suspension. STUDY DESIGN: A retrospective cohort study was performed in @entity0 who underwent laparoscopic uterosacral ligament suspension from 2010-2012. Only @entity0 with a preoperative pelvic magnetic resonance image were included. @entity1 was defined as a composite score that included the presence of anatomic bulge beyond the hymen with sensation of vaginal bulge or repeat treatment for prolapse via pessary or surgery by 1-year follow-up evaluation. Standard protocol pelvic magnetic resonance imaging measurements pubococcygeal line, H-line, and M-line were collected along with the calculation of the width of the levator ani hiatus. Estimated levator ani subtended volume was calculated for each subject. An optimal cutoff point was calculated and compared against categoric values of surgical success/failure. A Fisher exact test, an area under receiver operating characteristics curve, and logistic regression analysis were performed. A probability value of <.05 was considered statistically significant. RESULTS: Ninety-three @entity0 underwent laparoscopic bilateral uterosacral ligament suspension during study period. Of these, 66 @entity0 had a standardized preoperative pelvic magnetic resonance image per institutional protocol. Thirteen @entity0 (19.6%) met the criteria for @entity1 by 1 year. An optimal cutoff point of 38.5 was calculated by Liu's method for optimization. Among the @entity0 with defined surgical failures, 84.6% (11/13) had an estimated levator ani subtended volume above cutoff point of 38.5. Among the @entity0 with defined surgical success, 39.6% (21/53) had an estimated levator ani subtended volume above the cutoff point (84.6% vs 39.6%; P  = .0048) with a significant odds ratio of 8.38 (95% confidence interval, 1.69-41.68; P  = .009). An area under receiver operating characteristics curve of 0.725 (95% confidence interval, 0.603-0.847), sensitivity of 84.6% (95% confidence interval, 54.6%-98.1%), and specificity of 60.4% (95% confidence interval, 46%-73.5%) at 38.5 were predictors of surgical success/failure by 1 year. Logistic regression analysis demonstrated no significant confounders among age, body mass index, stage, or parity. CONCLUSIONS: Estimated levator ani subtended volume may predict @entity1 for laparoscopic bilateral uterosacral ligament suspension. @entity0 with a calculated estimated levator ani subtended volume above 38.5 on a preoperative pelvic magnetic resonance imaging were associated with an increased risk for @entity1 by 1 year, regardless of age, body mass index, stage, or parity. Future investigation that will include repeatability, reliability analysis, and a prospective study is warranted.

title: Estimated levator ani subtended volume: a novel assay for predicting XXXX after uterosacral ligament suspension.

answer: @entity1


abstract: OBJECTIVES: The isolation of @entity4 ( @entity4 ) on routine swabs taken from genitourinary medicine (GUM) clinic attendees is a common finding. The relation of @entity4 to @entity3 is unclear, creating @entity2 about management. This case-control study tested the hypothesis that detection of @entity4 on routine clinical specimens is not causally related to @entity3 in female GUM clinic attendees. METHODS: Data were collected on all female GUM clinic attendees who had @entity4 isolated from anogenital swabs between July 1999 and July 2001. Controls were randomly selected from all new and rebooking female GUM clinic attendees. Controls were group matched for age with cases and were included only if a sexual health screen was performed and the results of this were available. RESULTS: 118 cases and 308 controls were identified during the study period. There was no significant difference between cases and controls in @entity0 demographic or behavioural characteristics, the presence of @entity1 , or @entity3 . There was no relation between symptoms and quantitative growth of @entity4 reported by the laboratory in either cervical or urethral swabs. Only nine cases had high vaginal swabs taken, in whom there was a significant association between a heavy growth of @entity4 and @entity3 (p=0.008). CONCLUSION: The isolation of @entity4 from routinely collected genital swabs in female attendees of a GUM clinic is not causally related to @entity3 . We recommend that @entity0 should receive this advice and should not be treated with antibiotic therapy for this indication.

title: Group B streptococcus carriage and XXXX : causal or casual? A case-control study in a GUM clinic population.

answer: @entity3


abstract: BACKGROUND The endovascular approach has shown high initial technical success rates, good patency rates, and minimal complications in treating transplant @entity5 (TRAS). The objective of this study was to describe our experience with an endovascular approach to TRAS. MATERIAL AND METHODS We performed a retrospective single-institutional review of all kidney transplant procedures performed at our institution from September 2009 to September 2014. All consecutive cases of TRAS were included. RESULTS From a total of 183 kidney transplantations, 16 @entity0 had TRAS. Mean time from transplantation to TRAS diagnosis was 201.8 days. Stenoses or hemodynamic significant kinkings were located at the @entity2 (7), proximal (5) and middle (4) portions of the transplant artery. All @entity0 were treated with angioplasty and primary balloon-expanding stenting. Early technical success was 93.75% and local complication rate was 12.5%. No @entity1 occurred. Mean serum @entity4 level dropped from 3.87 mg/dL to 2.91 mg/dL after 24 hours; 1.85 mg/dL after one month; and 1.67 mg/dL after three months (P<0.05). Mean estimated glomerular filtration rate increased from 31.60 mL/min to 39.53 mL/min after 24 hours; 50.92 mL/min after one month; and 55.05 mL/min after three months (P<0.05). Doppler ultrasound criteria normalized after the procedure. Number of classes of antihypertensive drugs was not different before and after the procedure (P=0.38). Mean follow-up time was 9.75 months. One @entity0 had a @entity3 and required surgical intervention to restore graft function. CONCLUSIONS The endovascular approach to TRAS with primary balloon-expanding stenting was safe and had a high rate of technical success. It was effective for restore and maintain the renal function in transplant kidney grafts with a low rate of @entity3 .

title: Endovascular Approach to Transplant XXXX .

answer: @entity5


abstract: A 27-year old female was discovered at 4 a.m. lying in a wet field, the ambient temperature being of 4 degrees C. Her rectal temperature had fallen to 19 degrees C. She was @entity3 and failed to respond to noxious stimuli. Her pupils were dilated and fixed. Her respiratory rate was reduced to three to four breaths per min. Her blood pressure was not measurable and neither femoral or carotid pulse could be detected. The heart was in sinus rhythm with a rate of 40 b X @entity4 . During her transfer to hospital, she was ventilated with @entity2 , a tidal volume of 300 ml and a rate of 10 b X @entity4 . On arrival in the emergency room, a short period of @entity6 preceded @entity5 . Cardiac massage and @entity7 infusion were continued during the transfer of the @entity0 to the operating theatre. A femoro-femoral cardiopulmonary bypass was started with a bloodless priming, 3 mg X kg-1 heparin and a flow of 3,000 to 3,500 ml X @entity4 . Mean arterial pressure was maintained between 65 and 85 mmHg; cardiac massage was discontinued during the bypass. Within 50 min, @entity6 appeared, rectal temperature had increased to 33 degrees C. Electrical defibrillation (300 J) was successful. Cardiopulmonary bypass was stopped after 63 min. The postoperative course was uneventful, apart from transient @entity1 . At the time of discharge, a week later, no loss of intellect or change in behaviour could be perceived.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Accidental deep hypothermia and XXXX . Treatment with extracorporeal circulation].

answer: @entity5


abstract: @entity5 is an @entity6 associated with @entity3 , inflammatory, and autoimmune factors. Both humoral and cellular immune mechanisms have been proposed to participate in the onset and/or progression of @entity2 . @entity8 protein (hsp), oxidized low-density lipoprotein (LDL), and @entity11 have been reported to elicit humoral and cellular immune response in both experimental animals and @entity0 . These autoantigens are expressed within @entity5 . Immunization with the given autoantigens elicits an immune response that influences lesion progression. @entity5 susceptibility can be transferred by autoantigen-sensitized lymphocytes from immunized animals. @entity0 with @entity7 ( @entity7 ) and @entity9 ( @entity9 ) have a high risk for @entity1 events. The traditional risk factors fail to fully account for accelerated @entity5 in @entity7 and @entity9 . Immunological alterations, such as antibodies to oxidized LDL, antiphospholipid antibodies (aPL), antibodies to beta-2 Glycoprotein (anti- @entity10 -GPL), anti-prothrombin antibodies, may play a role in premature @entity5 in @entity7 and @entity9 . Paraoxonase ( @entity4 ) is an enzyme with antioxidant activity attached to the circulating high-density lipoprotein (HDL) in plasma. Its function is to prevent oxidation of LDL, thereby accounting for the antioxidant properties and the atherosclerotic protective effects of HDL. The relationship between @entity4 and aPL has been recently suggested. IgG anti-HDL and IgG anti- @entity11 antibodies were associated with reduced @entity4 activity in @entity0 with @entity7 and primary @entity9 . The determination of classic and new factors, together with specific autoantibody titers and the use of Doppler carotid ultrasound, are useful methods to detect early @entity5 in @entity7 and PAPS. Therapeutic strategies, including early control of disease and other risk factors, are essential to reduce morbidity and mortality.

title: @entity5 and XXXX .

answer: @entity9


abstract: @entity5 is an @entity6 associated with @entity3 , inflammatory, and autoimmune factors. Both humoral and cellular immune mechanisms have been proposed to participate in the onset and/or progression of @entity2 . @entity8 protein (hsp), oxidized low-density lipoprotein (LDL), and @entity11 have been reported to elicit humoral and cellular immune response in both experimental animals and @entity0 . These autoantigens are expressed within @entity5 . Immunization with the given autoantigens elicits an immune response that influences lesion progression. @entity5 susceptibility can be transferred by autoantigen-sensitized lymphocytes from immunized animals. @entity0 with @entity7 ( @entity7 ) and @entity9 ( @entity9 ) have a high risk for @entity1 events. The traditional risk factors fail to fully account for accelerated @entity5 in @entity7 and @entity9 . Immunological alterations, such as antibodies to oxidized LDL, antiphospholipid antibodies (aPL), antibodies to beta-2 Glycoprotein (anti- @entity10 -GPL), anti-prothrombin antibodies, may play a role in premature @entity5 in @entity7 and @entity9 . Paraoxonase ( @entity4 ) is an enzyme with antioxidant activity attached to the circulating high-density lipoprotein (HDL) in plasma. Its function is to prevent oxidation of LDL, thereby accounting for the antioxidant properties and the atherosclerotic protective effects of HDL. The relationship between @entity4 and aPL has been recently suggested. IgG anti-HDL and IgG anti- @entity11 antibodies were associated with reduced @entity4 activity in @entity0 with @entity7 and primary @entity9 . The determination of classic and new factors, together with specific autoantibody titers and the use of Doppler carotid ultrasound, are useful methods to detect early @entity5 in @entity7 and PAPS. Therapeutic strategies, including early control of disease and other risk factors, are essential to reduce morbidity and mortality.

title: XXXX and @entity9 .

answer: @entity5


abstract: STUDY OBJECTIVE: To determine the efficacy of intravenous @entity16 in the treatment of @entity0 hospitalized for exacerbation of @entity11 . DESIGN: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. @entity0 : Thirty @entity0 admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of @entity11 . Twenty-eight @entity0 completed the study; 2 @entity0 , 1 receiving placebo and 1 receiving @entity16 , were removed from the study because of @entity13 requiring mechanical ventilation. INTERVENTIONS: @entity0 received either intravenous @entity16 or placebo, in addition to nebulized, inhaled 0.3 mL of a 5% solution every 6 hours; @entity14 , 0.5 mg/kg body weight every 6 hours intravenously; @entity10 , 500 mg orally every 6 hours ( @entity9 or @entity4 - @entity5 were substituted in @entity3 - @entity2 @entity0 ); and supplemental @entity1 as needed. @entity16 infusion rates were adjusted by an unblinded investigator to achieve @entity15 levels of 72 to 83 mumol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. MEASUREMENTS AND MAIN RESULTS: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after @entity18 inhalation were measured twice daily by a blinded investigator, who also administered a verbal @entity12 index with a scale of 1 to 10 and questioned @entity0 regarding possible side effects of treatment ( @entity8 , palpitations, @entity6 , or @entity7 ). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after @entity18 treatment and in @entity12 occurred over time in both treatment groups (p less than 0.05 for all measurements). However, there were no significant differences between the placebo and @entity16 groups in any of the spirometric measurements or the @entity12 indices (p greater than 0.5 in all five analyses). The mean increases (+/- SE) in @entity17 of 1.9 (+/- 0.5) kPa with placebo and 1.7 (+/- 0.7) kPa with @entity16 and the mean decreases in PCO2 of 0.5 (+/- 0.4) kPa with placebo and 1.2 (+/- 0.4) kPa with @entity16 were not significantly different (p greater than 0.6 for @entity17 , p greater than 0.2 for PCO2).(ABSTRACT TRUNCATED AT 400 WORDS)

title: @entity16 for acute exacerbations of XXXX . A controlled trial.

answer: @entity11


abstract: STUDY OBJECTIVE: To determine the efficacy of intravenous @entity16 in the treatment of @entity0 hospitalized for exacerbation of @entity11 . DESIGN: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. @entity0 : Thirty @entity0 admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of @entity11 . Twenty-eight @entity0 completed the study; 2 @entity0 , 1 receiving placebo and 1 receiving @entity16 , were removed from the study because of @entity13 requiring mechanical ventilation. INTERVENTIONS: @entity0 received either intravenous @entity16 or placebo, in addition to nebulized, inhaled 0.3 mL of a 5% solution every 6 hours; @entity14 , 0.5 mg/kg body weight every 6 hours intravenously; @entity10 , 500 mg orally every 6 hours ( @entity9 or @entity4 - @entity5 were substituted in @entity3 - @entity2 @entity0 ); and supplemental @entity1 as needed. @entity16 infusion rates were adjusted by an unblinded investigator to achieve @entity15 levels of 72 to 83 mumol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. MEASUREMENTS AND MAIN RESULTS: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after @entity18 inhalation were measured twice daily by a blinded investigator, who also administered a verbal @entity12 index with a scale of 1 to 10 and questioned @entity0 regarding possible side effects of treatment ( @entity8 , palpitations, @entity6 , or @entity7 ). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after @entity18 treatment and in @entity12 occurred over time in both treatment groups (p less than 0.05 for all measurements). However, there were no significant differences between the placebo and @entity16 groups in any of the spirometric measurements or the @entity12 indices (p greater than 0.5 in all five analyses). The mean increases (+/- SE) in @entity17 of 1.9 (+/- 0.5) kPa with placebo and 1.7 (+/- 0.7) kPa with @entity16 and the mean decreases in PCO2 of 0.5 (+/- 0.4) kPa with placebo and 1.2 (+/- 0.4) kPa with @entity16 were not significantly different (p greater than 0.6 for @entity17 , p greater than 0.2 for PCO2).(ABSTRACT TRUNCATED AT 400 WORDS)

title: XXXX for acute exacerbations of @entity11 . A controlled trial.

answer: @entity16


abstract: OBJECTIVE: An advantage of surgical treatment over conservative treatment of spontaneous @entity3 ( @entity3 ) is controversial. Recent reports suggest that contrast extravasations on CT angiography (CTA) might serve as a crucial predictor of @entity2 expansion and mortality. The purpose of this study was aimed at investigating the efficacy of surgical treatment in @entity0 with spot sign positive @entity3 . METHODS: We used our institutional medical data search system to identify all adult @entity0 who admitted for treatment of @entity3 between January 1, 2007 and January 31, 2012. @entity0 were classified two groups into a surgical group (n=27) and a conservative treatment group (n=28). Admission criteria were the following: age 20-79 years, spontaneous supratentorial @entity3 , Glasgow @entity1 Score Ranging from 9 to 14, @entity3 volume >= 20 mL, and treatment within 24 hours. RESULTS: Fifty-five @entity0 were analyzed. There was no significant difference in the ICU stay between the conservative treatment group (7.36  3.66 days) and the surgical treatment group (6.93  2.20 days; p=0.950). There was a significant difference in the in-hospital stay between the conservative treatment group (13.93  8.87 days) and the surgical treatment group (20.33  6.37 days; p=0.001). Overall mortality at day 90 after @entity3 was 36.4%; this included 16 of 28 @entity0 (57.1%) in the conservative group and 4 of 27 @entity0 (14.8%) in the surgical group. In univariate analysis, there was a positive effect of the surgical treatment in reducing mortality at 90 days (p=0.002), Glasgow Outcome Scale (GOS) at 90-day (p=0.006), and @entity4 ( @entity4 ) at 90-day (p=0.023). In multivariate logistic analysis, there was a significant difference in mortality (odds ratio, 0.211; 95% confidence interval, 0.049-0.906; p=0.036) between the groups at 90-day follow-up. However, there was no significant difference in GOS (odds ratio, 0.371; 95% confidence interval, 0.031-4.446; p=0.434) and @entity4 (odds ratio, 1.041; 95% confidence interval, 0.086-12.637; p=0.975) between the groups at 90-day follow-up. CONCLUSION: In this study of surgical treatment of supratentorial @entity3 in @entity0 with spot sign positive in CTA was associated with less mortality despite of long duration of in-hospital stay. We failed to show that clinical outcome benefit of surgical treatment compared with conservative treatment in @entity0 with spot sign positive @entity3 .

title: Surgery versus Conservative Treatment for Spontaneous Supratentorial Intracerebral Hemorrhage in Spot Sign Positive XXXX .

answer: @entity0


abstract: OBJECTIVE: To determine whether the use of contrast enhancement (especially its extent) predicts @entity3 after intra-arterial thrombectomy (IAT) in @entity0 with acute @entity1 . METHODS: We reviewed the records of @entity0 with acute @entity1 who underwent IAT for occlusion of the internal carotid artery or the middle cerebral artery between January 2012 and March 2015. To estimate the extent of contrast enhancement (CE), we used the contrast enhancement area ratio (CEAR)-i.e., the ratio of the CE to the area of the hemisphere, as noted on immediate non-enhanced brain computed tomography (NECT) post-IAT. @entity0 were categorized into two groups based on the CEAR values being either greater than or less than 0.2. RESULTS: A total of 39 @entity0 were included. Contrast enhancement was found in 26 @entity0 (66.7%). In this subgroup, the CEAR was greater than 0.2 in 7 @entity0 (18%) and less than 0.2 in the other 19 @entity0 (48.7%). On univariate analysis, both CEAR >= 0.2 and the presence of @entity2 were significantly associated with progression to @entity3 (p<0.001 and p=0.004), but on multivariate analysis, only CEAR >= 0.2 showed a statistically significant association (p=0.019). In the group with CEAR >= 0.2, the time to @entity3 was shorter (p=0.039) than in the group with CEAR <0.2. Clinical functional outcomes, based on the modified Rankin scale, were also significantly worse in @entity0 with CEAR >= 0.2 (p=0.003). CONCLUSION: The extent of contrast enhancement as noted on NECT scans obtained immediately after IAT could be predictive of @entity3 and a poor clinical outcome.

title: Extent of Contrast Enhancement on Non-Enhanced Computed Tomography after Intra-Arterial Thrombectomy for Acute Infarction on Anterior Circulation: As a Predictive Value for Malignant XXXX .

answer: @entity3


abstract: BACKGROUND: Enterococci are opportunistic pathogens and are a major factor in @entity1 . They may contain @entity3 operon, which upon expression makes them highly prone to biofilm formation on biotic and abiotic surfaces. OBJECTIVES: The aim of the current study was to detect the polymorphism of @entity3 genes in @entity2 . MATERIALS AND METHODS: Samples were isolated from @entity0 (n = 58) and hospital environments (n = 32) of two hospitals in Tehran, Iran. All enterococcal species were identified by species-specific polymerase chain reaction (PCR); the antibiotic resistance pattern against nine antibiotics was determined. The @entity3 A, @entity3 B, @entity3 C and srt C genes were detected by PCR and the biofilm formation by the isolates was evaluated using the microtiter plate method. The genetic diversity of @entity3 genes was analyzed by restriction fragment length polymorphism (RFLP). RESULTS: The results indicated that, 86% of @entity0 and 29% of environmental isolates carried @entity3 genes. The ability of the isolates to strongly attach was 62% and 71% for @entity0 and environmental samples, respectively. The RFLP of the @entity3 showed no genetic variations amongst the isolates. CONCLUSIONS: The results of the antibiotic resistance and other data suggest that there is a possible common clone of @entity2 , which could rapidly disseminate in @entity0 and the environment.

title: Antibiotic Resistance and Biofilm Formation of XXXX in @entity0 and Environmental Samples.

answer: @entity2


abstract: BACKGROUND: Enterococci are opportunistic pathogens and are a major factor in @entity1 . They may contain @entity3 operon, which upon expression makes them highly prone to biofilm formation on biotic and abiotic surfaces. OBJECTIVES: The aim of the current study was to detect the polymorphism of @entity3 genes in @entity2 . MATERIALS AND METHODS: Samples were isolated from @entity0 (n = 58) and hospital environments (n = 32) of two hospitals in Tehran, Iran. All enterococcal species were identified by species-specific polymerase chain reaction (PCR); the antibiotic resistance pattern against nine antibiotics was determined. The @entity3 A, @entity3 B, @entity3 C and srt C genes were detected by PCR and the biofilm formation by the isolates was evaluated using the microtiter plate method. The genetic diversity of @entity3 genes was analyzed by restriction fragment length polymorphism (RFLP). RESULTS: The results indicated that, 86% of @entity0 and 29% of environmental isolates carried @entity3 genes. The ability of the isolates to strongly attach was 62% and 71% for @entity0 and environmental samples, respectively. The RFLP of the @entity3 showed no genetic variations amongst the isolates. CONCLUSIONS: The results of the antibiotic resistance and other data suggest that there is a possible common clone of @entity2 , which could rapidly disseminate in @entity0 and the environment.

title: Antibiotic Resistance and Biofilm Formation of @entity2 in XXXX and Environmental Samples.

answer: @entity0


abstract: OBJECTIVE: Platelet-activating factor (PAF) is a potent proinflammatory mediator implicated in the pathogenesis of both severe @entity2 and @entity3 . One of the regulatory pathways for PAF involves degradation to the inactive metabolite lyso-PAF by the enzyme @entity5 ( @entity5 ). Because reduced concentrations of the natural form of @entity5 have been reported in septic @entity0 , the present study was conducted to determine whether treatment with recombinant @entity0 @entity5 (rPAF-AH, Pafase) was safe when administered after the onset of severe @entity2 and whether it decreases the prevalence of @entity3 and 28-day all-cause mortality. DESIGN: A prospective, randomized, double-blind, placebo-controlled, multicenter trial. SETTING: Thirty-three medical and surgical intensive care units located in the United States. @entity0 : A total of 127 @entity0 with severe @entity2 , but without established @entity3 , were enrolled in the study. Randomization occurred within 12 hrs of the onset of severe @entity2 . @entity0 then received 1.0 mg/kg rPAF-AH (n = 45), 5.0 mg/kg rPAF-AH (n = 39), or placebo (n = 43) administered intravenously, once daily, for five consecutive days. MEASUREMENTS AND MAIN RESULTS: Demographic and baseline clinical characteristics of the three treatment groups were similar, except for a significantly higher prevalence of @entity4 as the cause of severe @entity2 in @entity0 treated with 1.0 mg/kg rPAF-AH. There were no treatment-related @entity1 , and the overall prevalence of adverse events was similar among rPAF-AH-treated and placebo-treated @entity0 . There were no significant differences in the prevalence of @entity3 among the three treatment groups. However, 28-day all-cause mortality was 21% in the 1.0 mg/kg rPAF-AH group, 28% in the 5.0 mg/kg rPAF-AH group, and 44% in the placebo group (overall chi-square p =.07; 1.0 mg/kg rPAF-AH vs. placebo, p =.03). A trend toward reduced multiple organ dysfunction also was observed in the 1.0 mg/kg rPAF-AH group compared with the placebo group (p =.11). CONCLUSION: The results from this study indicate that rPAF-AH was well tolerated and should be pursued as a potential new treatment to decrease mortality in @entity0 with severe @entity2 .

title: Recombinant platelet-activating factor acetylhydrolase to prevent @entity3 and mortality in severe XXXX : Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.

answer: @entity2


abstract: OBJECTIVE: Platelet-activating factor (PAF) is a potent proinflammatory mediator implicated in the pathogenesis of both severe @entity2 and @entity3 . One of the regulatory pathways for PAF involves degradation to the inactive metabolite lyso-PAF by the enzyme @entity5 ( @entity5 ). Because reduced concentrations of the natural form of @entity5 have been reported in septic @entity0 , the present study was conducted to determine whether treatment with recombinant @entity0 @entity5 (rPAF-AH, Pafase) was safe when administered after the onset of severe @entity2 and whether it decreases the prevalence of @entity3 and 28-day all-cause mortality. DESIGN: A prospective, randomized, double-blind, placebo-controlled, multicenter trial. SETTING: Thirty-three medical and surgical intensive care units located in the United States. @entity0 : A total of 127 @entity0 with severe @entity2 , but without established @entity3 , were enrolled in the study. Randomization occurred within 12 hrs of the onset of severe @entity2 . @entity0 then received 1.0 mg/kg rPAF-AH (n = 45), 5.0 mg/kg rPAF-AH (n = 39), or placebo (n = 43) administered intravenously, once daily, for five consecutive days. MEASUREMENTS AND MAIN RESULTS: Demographic and baseline clinical characteristics of the three treatment groups were similar, except for a significantly higher prevalence of @entity4 as the cause of severe @entity2 in @entity0 treated with 1.0 mg/kg rPAF-AH. There were no treatment-related @entity1 , and the overall prevalence of adverse events was similar among rPAF-AH-treated and placebo-treated @entity0 . There were no significant differences in the prevalence of @entity3 among the three treatment groups. However, 28-day all-cause mortality was 21% in the 1.0 mg/kg rPAF-AH group, 28% in the 5.0 mg/kg rPAF-AH group, and 44% in the placebo group (overall chi-square p =.07; 1.0 mg/kg rPAF-AH vs. placebo, p =.03). A trend toward reduced multiple organ dysfunction also was observed in the 1.0 mg/kg rPAF-AH group compared with the placebo group (p =.11). CONCLUSION: The results from this study indicate that rPAF-AH was well tolerated and should be pursued as a potential new treatment to decrease mortality in @entity0 with severe @entity2 .

title: Recombinant platelet-activating factor acetylhydrolase to prevent XXXX and mortality in severe @entity2 : Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.

answer: @entity3


abstract: INTRODUCTION: In addition to its effects on platelet function, recent studies suggest that inhaled @entity2 (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in @entity0 with acute @entity1 . METHODS: In 16 @entity0 responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet @entity5 expression, platelet fibrinogen binding, the expression @entity3 on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, @entity4 was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated @entity0 without acute @entity1 and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. RESULTS: NO therapy inhibited @entity4 formation at 60 (13% +/- 4% in the NO group vs. 19% +/- 7% in the control group, p <.01) and 120 mins (14% +/- 4% vs. 18% +/- 7%, p <.05) and slightly decreased @entity3 expression at 60 mins (152 +/- 22 arbitrary units vs. 187 +/- 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of @entity5 expression at 120 (38% +/- 4% vs. 43% +/- 5%, p <.05) and 180 mins (34% +/- 5% vs. 43% +/- 6%, p <.01), demonstrating a significant correlation between changes in @entity5 expression and @entity4 formation. In contrast, @entity4 formation was not influenced by mechanical ventilation in @entity0 without acute @entity1 . These results were further supported by additional studies showing inhibition of @entity4 formation in healthy volunteers as well. CONCLUSIONS: NO-dependent inhibition of @entity4 formation in @entity0 with acute @entity1 can be explained by the inhibition in platelet @entity5 expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.

title: Inhaled XXXX inhibits platelet-leukocyte interactions in @entity0 with acute @entity1 .

answer: @entity2


abstract: INTRODUCTION: In addition to its effects on platelet function, recent studies suggest that inhaled @entity2 (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in @entity0 with acute @entity1 . METHODS: In 16 @entity0 responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet @entity5 expression, platelet fibrinogen binding, the expression @entity3 on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, @entity4 was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated @entity0 without acute @entity1 and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. RESULTS: NO therapy inhibited @entity4 formation at 60 (13% +/- 4% in the NO group vs. 19% +/- 7% in the control group, p <.01) and 120 mins (14% +/- 4% vs. 18% +/- 7%, p <.05) and slightly decreased @entity3 expression at 60 mins (152 +/- 22 arbitrary units vs. 187 +/- 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of @entity5 expression at 120 (38% +/- 4% vs. 43% +/- 5%, p <.05) and 180 mins (34% +/- 5% vs. 43% +/- 6%, p <.01), demonstrating a significant correlation between changes in @entity5 expression and @entity4 formation. In contrast, @entity4 formation was not influenced by mechanical ventilation in @entity0 without acute @entity1 . These results were further supported by additional studies showing inhibition of @entity4 formation in healthy volunteers as well. CONCLUSIONS: NO-dependent inhibition of @entity4 formation in @entity0 with acute @entity1 can be explained by the inhibition in platelet @entity5 expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.

title: Inhaled @entity2 inhibits platelet-leukocyte interactions in @entity0 with acute XXXX .

answer: @entity1


abstract: INTRODUCTION: In addition to its effects on platelet function, recent studies suggest that inhaled @entity2 (NO) also influences the function of circulating leukocytes. Therefore, the aim of this work was to investigate the formation of platelet-leukocyte aggregates (PLAs) and platelet and leukocyte cell surface receptor expression during NO therapy in @entity0 with acute @entity1 . METHODS: In 16 @entity0 responding to NO therapy with an improvement in oxygenation (NO group) and in four nonresponders (control), platelet @entity5 expression, platelet fibrinogen binding, the expression @entity3 on leukocytes, and the formation of PLAs were investigated at 0, 60, 120, and 180 mins of therapy or at corresponding time points by means of flow cytometry. In addition, @entity4 was investigated in 30 healthy volunteers during NO inhalation, in five mechanically ventilated @entity0 without acute @entity1 and without NO inhalation, and during NO incubation in platelet-rich plasma of ten healthy volunteers in vitro. RESULTS: NO therapy inhibited @entity4 formation at 60 (13% +/- 4% in the NO group vs. 19% +/- 7% in the control group, p <.01) and 120 mins (14% +/- 4% vs. 18% +/- 7%, p <.05) and slightly decreased @entity3 expression at 60 mins (152 +/- 22 arbitrary units vs. 187 +/- 36 arbitrary units, p <.05). Furthermore, besides inhibiting platelet fibrinogen binding, NO also led to a significant inhibition of @entity5 expression at 120 (38% +/- 4% vs. 43% +/- 5%, p <.05) and 180 mins (34% +/- 5% vs. 43% +/- 6%, p <.01), demonstrating a significant correlation between changes in @entity5 expression and @entity4 formation. In contrast, @entity4 formation was not influenced by mechanical ventilation in @entity0 without acute @entity1 . These results were further supported by additional studies showing inhibition of @entity4 formation in healthy volunteers as well. CONCLUSIONS: NO-dependent inhibition of @entity4 formation in @entity0 with acute @entity1 can be explained by the inhibition in platelet @entity5 expression. Thus, this study provides rational evidence of systemic antileukocytic and antiplatelet properties of NO therapy in the clinical setting.

title: Inhaled @entity2 inhibits platelet-leukocyte interactions in XXXX with acute @entity1 .

answer: @entity0


abstract: UNASSIGNED: The Omura's whale ( @entity2 ) was described as a new species in 2003 and then soon after as an ancient lineage basal to a Bryde's/ @entity1 clade. Currently known only from whaling and stranding specimens primarily from the western Pacific and eastern Indian Oceans, there exist no confirmed field observations or ecological/behavioural data. Here we present, to our knowledge, the first genetically confirmed documentation of living Omura's whales including descriptions of basic ecology and behaviour from northwestern Madagascar. Species identification was confirmed through molecular phylogenetic analyses of biopsies collected from 18 adult animals. All individuals shared a single haplotype in a 402 bp sequence of mtDNA control region, suggesting low diversity and a potentially small population. Sightings of 44 groups indicated preference for shallow-water shelf habitat with sea surface temperature between 27.4  C and 30.2  C. Frequent observations were made of lunge feeding, possibly on zooplankton. Observations of four mothers with young @entity0 , and recordings of a song-like vocalization probably indicate reproductive behaviour. Social organization consisted of loose aggregations of predominantly unassociated single individuals spatially and temporally clustered. Photographic recapture of a female re-sighted the following year with a young @entity0 suggests site fidelity or a resident population. Our results demonstrate that the species is a tropical whale without segregation of feeding and breeding habitat, and is probably non-migratory; our data extend the range of this poorly studied whale into the western Indian Ocean. Exclusive range restriction to tropical waters is rare among baleen whale species, except for the various forms of @entity3 and Omura's whales. Thus, the discovery of a tractable population of Omura's whales in the tropics presents an opportunity for understanding the ecological factors driving potential convergence of life-history patterns with the distantly related @entity3 .

title: Omura's whales ( XXXX ) off northwest Madagascar: ecology, behaviour and conservation needs.

answer: @entity2


abstract: BACKGROUND: The goal was to assess a possible relationship between the detection of mRNA from @entity2 gene in cerebrospinal fluid (CSF) and neoplastic relapse in pediatric @entity0 being treated for lymphoid precursor cell neoplasms. @entity0 AND METHODS: Ninety-four @entity0 less than 19 years old with lymphoid precursor cell @entity1 in hematologic remission and without central nervous system (CNS) compromise were included. Cytology, cytochemistry, cell count, and qualitative RT-PCR were performed using routine CSF samples obtained during intrathecal chemotherapy administration. The main outcome measure was clinical, radiologic, and cytologic evidence of CNS, hematologic or any other type of neoplastic relapse. RESULTS: At some time during follow-up, 28.7% of the @entity0 had a positive @entity2 CSF test. Relapses included 10 @entity0 with isolated hematologic, 4 with isolated CNS, 1 with combined CNS and hematologic, and 1 with mediastinal relapse; the maximal follow-up period was 312 days. A statistically significant association was found between the detection of @entity2 in CSF and CNS relapse. Adjusted hazard rate ratios of 5.04 (95% confidence interval 1.33-19.12) and 7.48 (2.34-23.93) were estimated for isolated hematologic relapse and for all types of relapses, respectively. CONCLUSIONS: Although it is likely that the short follow-up period underestimated the incidence of relapse, this study was able to identify a strong association between @entity2 mRNA detection and CNS or hematologic relapse. These findings represent a potentially novel and useful approach for subclinical disease detection.

title: XXXX mRNA in cerebrospinal fluid associated with relapse in pediatric lymphoblastic leukemia.

answer: @entity2


abstract: PURPOSE: The purpose of the current study was to define the imaging findings of @entity2 ( @entity2 ) and correlate them with clinicopathologic features. MATERIALS AND METHODS: The CT scans and MR images of six @entity0 with histologically confirmed @entity2 (mean age, 49 years) were retrospectively analyzed. RESULTS: The arising sites of @entity1 included the retroperitoneum (n = 2), pelvis (n = 2), anterior @entity4 (n = 1), and adrenal gland (n = 1). The common CT finding was poorly marginated and heterogeneous mass without @entity3 . Cystic components were often found. On contrast-enhanced CT or MR images, @entity1 showed heterogeneous enhancement. On T2-weighted images, all masses demonstrated predominantly hyper signal intensity relative to skeletal muscle and the images showed heterogeneous appearance with focal areas of high intensity interspersed with septations of low signal intensity. Soft tissue masses with bone involvement were identified in one case on MR images. The CT findings in one @entity1 originating from @entity4 were similar to those of @entity1 arising from other sites. CONCLUSION: @entity2 is an uncommon @entity1 that often pursues an aggressive clinical course, involves multiple sites, and has a poor prognosis. Tumors usually manifest on CT or MR images as a poorly demarcated mass mainly in the retroperitoneum and pelvis. Imaging studies can depict aggressive characteristics and disease extent of @entity2 .

title: XXXX : radiologic and clinicopathologic features.

answer: @entity2


abstract: OBJECTIVE: Evaluate precautionary practices and extent of use of @entity3 ( @entity2 ) and @entity1 gas plasma (HPGP) sterilization systems, including use of single chamber @entity2 units. DESIGN: Modular, web-based survey. @entity0 : Members of professional practice organizations who reported using @entity2 or HPGP in the past week to sterilize medical instruments and supplies. Participating organizations invited members via email which included a hyperlink to the survey. METHODS: Descriptive analyses were conducted including simple frequencies and prevalences. RESULTS: A total of 428 respondents completed the module on chemical sterilants. Because most respondents worked in hospitals (87%, n=373) analysis focused on these workers. Most used HPGP sterilizers (84%, n=373), 38% used @entity2 sterilizers, with 22% using both. Nearly all respondents using @entity2 operated single chamber units (94%, n=120); most of them reported that the units employed single use cartridges (83%, n=115). Examples of where engineering and administrative controls were lacking for @entity2 include: operational local exhaust ventilation (7%; n=114); continuous air monitoring (6%; n=113); safe handling training (6%; n=142); and standard operating procedures (4%; n=142). Examples of practices which may increase HPGP exposure risk included lack of standard operating procedures (9%; n=311) and safe handling training (8%; n=312). CONCLUSIONS: Use of precautionary practices was good but not universal. @entity2 use appears to have diminished in favor of HPGP which affords higher throughput and minimal regulatory constraints. Separate @entity2 sterilization and aeration units were still being used nearly one year after U.S. EPA prohibited their use.

title: @entity3 and XXXX Gas Plasma Sterilization: Precautionary Practices in U.S. Hospitals.

answer: @entity1


abstract: OBJECTIVE: Evaluate precautionary practices and extent of use of @entity3 ( @entity2 ) and @entity1 gas plasma (HPGP) sterilization systems, including use of single chamber @entity2 units. DESIGN: Modular, web-based survey. @entity0 : Members of professional practice organizations who reported using @entity2 or HPGP in the past week to sterilize medical instruments and supplies. Participating organizations invited members via email which included a hyperlink to the survey. METHODS: Descriptive analyses were conducted including simple frequencies and prevalences. RESULTS: A total of 428 respondents completed the module on chemical sterilants. Because most respondents worked in hospitals (87%, n=373) analysis focused on these workers. Most used HPGP sterilizers (84%, n=373), 38% used @entity2 sterilizers, with 22% using both. Nearly all respondents using @entity2 operated single chamber units (94%, n=120); most of them reported that the units employed single use cartridges (83%, n=115). Examples of where engineering and administrative controls were lacking for @entity2 include: operational local exhaust ventilation (7%; n=114); continuous air monitoring (6%; n=113); safe handling training (6%; n=142); and standard operating procedures (4%; n=142). Examples of practices which may increase HPGP exposure risk included lack of standard operating procedures (9%; n=311) and safe handling training (8%; n=312). CONCLUSIONS: Use of precautionary practices was good but not universal. @entity2 use appears to have diminished in favor of HPGP which affords higher throughput and minimal regulatory constraints. Separate @entity2 sterilization and aeration units were still being used nearly one year after U.S. EPA prohibited their use.

title: XXXX and @entity1 Gas Plasma Sterilization: Precautionary Practices in U.S. Hospitals.

answer: @entity3


abstract: UNASSIGNED: Primary @entity2 (PRM) is a rare variant of @entity2 . Herein, we describe a case of primary @entity8 and review the clinicopathological features of previously reported cases of PRMs. A 63-year-old Japanese @entity0 presented with a nonpigmented red granular @entity1 without peripheral pigmented macules on the left heel measuring 21 * 18 mm in size. Light microscopic examination revealed a @entity1 mass composed entirely of polygonal neoplastic cells resembling pulmonary alveoli. @entity1 cells were also discohesive with bizarre nuclei, prominent nucleoli and large hyaline cytoplasmic inclusions. No melanin pigment was present. @entity1 cells were strongly and diffusely positive for @entity5 , @entity9 , HMB-45 and @entity4 , while negative for @entity6 , @entity3 and @entity7 . According to previous reviews, PRM tends to be amelanotic and nodular. @entity5 protein and @entity4 stained in all cases contrary to low stainability for HMB-45, which was, by contrast, positive in our case. Prognosis of PRM remains controversial due to the very rare occurrence of this @entity1 and the small number of confirmed cases that have been reported. Recognition of this rare entity is important in clinical practice even for skillful dermatologists to avoid misdiagnosis with the other @entity1 and to determinate the subsequent treatment principles.

title: Primary XXXX : A Case Report with Review of the Literature.

answer: @entity8


abstract: A 36-year-old @entity0 was referred to our hospital with complaints of high fever and @entity1 . A diagnosis of @entity12 with @entity6 was made. He was treated with @entity7 (400 mg/day), @entity4 (300 mg/day), @entity8 (750 mg/day), @entity10 (1.0 g/day) and @entity2 (60 mg/day). However, he lost consciousness because of @entity5 on the second day of hospitalization. Emergency cerebrospinal fluid drainage improved his neurological symptoms. After two months, he again complained of @entity1 with @entity3 . Numerous @entity11 were found not only in the cerebrum but also in the liver, the spleen and the retina. Recurrent @entity5 was treated with a V-P shunt, and combination therapy with four antituberculous agents was maintained for 18 months. He was discharged in a healthy condition, although a mild @entity9 remained. In addition, we examined the inflammatory cytokine levels in both the CSF and the serum over the period of the @entity0 's hospitalization. We concluded that the cytokine levels in the CSF may be associated with the progress and the prognosis of @entity6 .

title: [An adult case of XXXX ].

answer: @entity6


abstract: The ASEP/ @entity0 (averaged solvent electrostatic potential from molecular dynamics) method was employed in studying the environment effects (solvent and counterion) on the absorption spectrum of a model of the 11-cis-retinal protonated @entity3 . Experimental studies of the absorption spectra of the @entity4 chromophore show anomalously large solvent shifts in apolar solvents. In order to clarify their origin, we study the role of the counterion and of the solute-solvent interactions. We compare the absorption spectra in the gas phase, @entity5 , @entity2 , and @entity1 . The counterion effect was described from both a classical and quantum point of view. In the latter case, the contribution of the chromophore-counterion charge transfer to the solvent shift could be analyzed. To the best of our knowledge, this is the first time that counterion and solvent effects on the absorption properties of the 11-cis-retinal chromophore have been simultaneously examined. We conclude that the counterion-solute ionic pair in the gas phase is not a good model to represent the solvent shift in nonpolar solvents, as it does not account for the effect that the thermal agitation of the solvent has on the geometry of the ionic pair. In contrast to nonpolar solvents, the experimental solvent shift values in @entity1 can be exclusively explained by the polarity of the medium. In @entity2 , the presence of the counterion does not modify the solvent shift of the first absorption band, but it affects the position of the second excited state. In the three solvents considered, the first two excited states become almost degenerate.

title: Simultaneous Solvent and Counterion Effects on the Absorption Properties of a Model of the XXXX Chromophore.

answer: @entity4


abstract: BACKGROUND: The literature investigating pancreatic invasive @entity4 ( @entity4 ) has largely come from small institutional studies, preventing adequately powered comparisons of adjuvant therapy versus surgery alone (SA) within specific @entity0 subgroups. METHODS: @entity0 with resected, stage I through IV, invasive @entity4 and conventional @entity2 ( @entity2 ) were identified in the National @entity1 Data Base (1998-2010). Cox modeling of @entity0 with invasive @entity4 was used to compare @entity3 ( @entity3 ) between @entity0 who received adjuvant therapy and those who underwent SA. A second model was used to compare @entity3 between @entity0 with invasive @entity4 and those with @entity2 . RESULTS: For the 1220 @entity0 with invasive @entity4 , the median @entity3 was 28.9 months; the 1-year and 5-year actuarial survival rates were 76% and 17%, respectively; and 47% received adjuvant therapy. Cox modeling associated SA with worse @entity3 (hazard ratio, 1.36; 95% confidence interval, 1.17-1.58; P   =   .00005) as well as American Joint Committee on @entity1 (AJCC) TNM stage III/IV disease, positive lymph node status, positive margins, and poor @entity1 differentiation (all P    <=   .05). In addition, Cox modeling stratified by the following characteristics demonstrated improved @entity3 with adjuvant therapy: AJCC TNM stage II or III/IV, positive lymph node status, positive margins, and poorly differentiated @entity1 . There was no survival advantage from adjuvant therapy for @entity0 who had AJCC TNM stage I or lymph node-negative disease. @entity0 who had invasive @entity4 had improved risk-adjusted @entity3 compared with those who had @entity2 (hazard ratio, 0.73; 95% confidence interval, 0.68-0.78; P   <   .00001). CONCLUSIONS: Invasive @entity4 appears to be more indolent than conventional @entity2 . Adjuvant therapy is associated with improved @entity3 compared with SA in @entity0 with invasive @entity4 , especially for those with higher stage disease, positive lymph nodes, positive margins, or poorly differentiated @entity1 . Conversely, this benefit does not extend to @entity0 with stage I or lymph node-negative disease. @entity1 2016;122:521-533.    2015 American @entity1 Society.

title: The efficacy of adjuvant therapy for pancreatic invasive XXXX ( @entity4 ).

answer: @entity4


abstract: BACKGROUND: The literature investigating pancreatic invasive @entity4 ( @entity4 ) has largely come from small institutional studies, preventing adequately powered comparisons of adjuvant therapy versus surgery alone (SA) within specific @entity0 subgroups. METHODS: @entity0 with resected, stage I through IV, invasive @entity4 and conventional @entity2 ( @entity2 ) were identified in the National @entity1 Data Base (1998-2010). Cox modeling of @entity0 with invasive @entity4 was used to compare @entity3 ( @entity3 ) between @entity0 who received adjuvant therapy and those who underwent SA. A second model was used to compare @entity3 between @entity0 with invasive @entity4 and those with @entity2 . RESULTS: For the 1220 @entity0 with invasive @entity4 , the median @entity3 was 28.9 months; the 1-year and 5-year actuarial survival rates were 76% and 17%, respectively; and 47% received adjuvant therapy. Cox modeling associated SA with worse @entity3 (hazard ratio, 1.36; 95% confidence interval, 1.17-1.58; P   =   .00005) as well as American Joint Committee on @entity1 (AJCC) TNM stage III/IV disease, positive lymph node status, positive margins, and poor @entity1 differentiation (all P    <=   .05). In addition, Cox modeling stratified by the following characteristics demonstrated improved @entity3 with adjuvant therapy: AJCC TNM stage II or III/IV, positive lymph node status, positive margins, and poorly differentiated @entity1 . There was no survival advantage from adjuvant therapy for @entity0 who had AJCC TNM stage I or lymph node-negative disease. @entity0 who had invasive @entity4 had improved risk-adjusted @entity3 compared with those who had @entity2 (hazard ratio, 0.73; 95% confidence interval, 0.68-0.78; P   <   .00001). CONCLUSIONS: Invasive @entity4 appears to be more indolent than conventional @entity2 . Adjuvant therapy is associated with improved @entity3 compared with SA in @entity0 with invasive @entity4 , especially for those with higher stage disease, positive lymph nodes, positive margins, or poorly differentiated @entity1 . Conversely, this benefit does not extend to @entity0 with stage I or lymph node-negative disease. @entity1 2016;122:521-533.    2015 American @entity1 Society.

title: The efficacy of adjuvant therapy for pancreatic invasive @entity4 ( XXXX ).

answer: @entity4